

TITLE

Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein after infection and/or vaccination

AUTHORS

Meghan E. Garrett^{*1,2}, Jared G. Galloway^{*3}, Caitlin Wolf⁴, Jennifer K. Logue⁴, Nicholas Franko⁴, Helen Y. Chu⁴, Frederick A. Matsen IV^{3,5}, Julie Overbaugh^{1,3}

* these authors contributed equally to this work.

^ co-corresponding authors

Corresponding authors emails: joverbau@fredhutch.org, matsen@fredhutch.org

¹ Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98102, USA

² Molecular and Cellular Biology Graduate Program, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA 98195, USA

³ Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98102, USA

⁴ Department of Medicine, University of Washington, Seattle, WA 98195, USA

⁵ Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98102, USA

ABSTRACT

Background: Control of the COVID-19 pandemic will rely on SARS-CoV-2 vaccine-elicited antibodies to protect against emerging and future variants; an understanding of the unique features of the humoral responses to infection and vaccination, including different vaccine platforms, is needed to achieve this goal.

Methods: The epitopes and pathways of escape for Spike-specific antibodies in individuals with diverse infection and vaccination history were profiled using Phage-DMS. Principal component analysis was performed to identify regions of antibody binding along the Spike protein that differentiate the samples from one another. Within these epitope regions we determined potential escape mutations by comparing antibody binding of peptides containing wildtype residues versus peptides containing a mutant residue.

Results: Individuals with mild infection had antibodies that bound to epitopes in the S2 subunit within the fusion peptide and heptad-repeat regions, whereas vaccinated individuals had antibodies that additionally bound to epitopes in the N- and C-terminal domains of the S1 subunit, a pattern that was also observed in individuals with severe disease due to infection. Epitope binding appeared to change over time after vaccination, but other covariates such as mRNA vaccine dose, mRNA vaccine type, and age did not affect antibody binding to these epitopes. Vaccination induced a relatively uniform escape profile across individuals for some epitopes, whereas there was much more variation in escape pathways in mildly infected individuals. In the case of antibodies targeting the fusion peptide region, which was a common response to both infection and vaccination, the escape profile after infection was not altered by subsequent vaccination.

Conclusions: The finding that SARS-CoV-2 mRNA vaccination resulted in binding to additional epitopes beyond what was seen after infection suggests protection could vary depending on the route of exposure to Spike antigen. The relatively conserved escape pathways to vaccine-induced

antibodies relative to infection-induced antibodies suggests that if escape variants emerge, they may be readily selected for across vaccinated individuals. Given that the majority of people will be first exposed to Spike via vaccination and not infection, this work has implications for predicting the selection of immune escape variants at a population level.

Funding: This work was supported by NIH grants AI138709 (PI Overbaugh) and AI146028 (PI Matsen). Julie Overbaugh received support as the Endowed Chair for Graduate Education (FHCRG). The research of Frederick Matsen was supported in part by a Faculty Scholar grant from the Howard Hughes Medical Institute and the Simons Foundation. Scientific Computing Infrastructure at Fred Hutch was funded by ORIP grant S10OD028685.

INTRODUCTION

The future of the COVID-19 pandemic will be determined in large part by the ability of vaccine-elicited immunity to protect against current and future variants of the SARS-CoV-2 virus. Several vaccines have now been approved for use in multiple countries, including two that are based on mRNA technology: BNT162b2 (Pfizer/BioNTech) and mRNA-1273 (Moderna). In the United States, over half of adults are now vaccinated against SARS-CoV-2, the majority of whom have received one of these mRNA vaccines. While these vaccines have been shown to effectively guard against infection, severe disease, and death related to SARS-CoV-2¹⁻⁷, less is known about how effective they will be against emerging and future variants. Current surges in the Delta variant coupled with reports of reduced potency of vaccine elicited antibodies against this variant highlight this concerning ongoing dynamic^{8,9}. Evidence from related endemic coronaviruses indicates that evolution in the Spike protein results in escape from neutralizing antibodies elicited by prior infection¹⁰, potentially contributing to why endemic coronaviruses can reinfect the same host¹¹⁻¹³. Without immunity that is robust in the face of antigenic drift, continual updates of the vaccine to combat new SARS-CoV-2 variants will likely be necessary to provide optimal protection against symptomatic infection.

Prior infection with SARS-CoV-2 also provides some immunity against subsequent re-infection, and several studies have characterized the epitopes targeted by convalescent sera¹⁴⁻¹⁸. It is currently unknown whether SARS-CoV-2 infection and vaccination result in antibodies that bind to similar epitopes, an important point to consider given that most people have acquired antibodies through immunization and not infection. The Spike protein encoded by the mRNA in both SARS-CoV-2 vaccines is stabilized in the prefusion conformation by addition of two proline substitutions¹⁹. This change in sequence and fixed conformation of the Spike protein could result in altered antibody targeting when compared to antibodies elicited during infection, where Spike undergoes several conformational changes. It is also possible that differences in antibody specificity could be due to the amount of antigen or type of immune response stimulated in the context of infection versus vaccination. We know that vaccines drive higher neutralization titers and more Spike binding IgG antibodies than infection²⁰⁻²², indicating some differences in the B cell response compared to infection. A recent study showed that antibodies against the receptor binding domain (RBD) of Spike differ between infected and vaccinated individuals; they are generally less sensitive to mutation and bind more broadly across the domain in the context of vaccination as compared to infection²³.

Although the majority of the serum binding response in SARS-CoV-2 infected and vaccinated people is directed towards regions of the protein outside of the RBD epitopes^{15,23-25}, few studies have examined the prevalence and escape pathways of these antibodies, especially in the setting of vaccination. Antibodies to linear epitopes in the S2 domain of Spike overlapping the fusion peptide (FP), and in the stem helix region just upstream of heptad repeat 2 (SH-H) region are found in serum from COVID-19 patients, and some studies suggest these antibodies may be neutralizing^{26,27}. These

97 non-RBD responses may also be important contributors to non-neutralizing antibody activities, which
98 have been associated with protection and therapeutic benefit in experimental SARS-CoV-2 models
99 and with vaccine protection²⁸⁻³¹. Importantly, these epitopes lie in more conserved regions of Spike
100 than RBD where functional constraints on variation may counter the selective pressure for viral
101 escape.

102 To compare antibody immunity elicited by SARS-CoV-2 infection and vaccination, we used a
103 high-resolution Spike-specific deep mutational scanning phage display library to profile the epitopes
104 and sites of escape for serum antibodies from people who had been infected, vaccinated, or a
105 combination of both. This approach, called Phage-DMS, identified four non-RBD antibody binding
106 epitopes across all samples: the FP and SH-H region in the S2 subunit, and the N-terminal and C-
107 terminal domains (NTD and CTD, respectively) in the S1 subunit of Spike. Antibodies to NTD and
108 CTD were uniquely present in the setting of mRNA vaccination or severe infection, but mostly absent
109 in mild COVID-19 cases. In vaccinated individuals, the magnitude of the response varied over time
110 both to the CTD and SH-H epitopes. Other covariates, such as age, dose, and vaccine type had no
111 significant differences in the binding profiles observed. Of particular relevance to protection against
112 emerging variants, infection and vaccination appear to shape the pathways of escape differently in
113 different epitopes. In the FP epitope, which is a dominant response after infection, the escape
114 pathway was maintained after subsequent vaccination; in the SH-H epitope, infection resulted in
115 antibodies with diverse pathways of escape, whereas vaccination induced a highly uniform escape
116 profile across individuals. Overall, these findings indicate that vaccination induced a broader antibody
117 response across the Spike protein but induced a singular antibody response at the SH-H epitope,
118 which could favor variants that emerge with these mutations.

121 RESULTS

123 Samples from individuals with varying SARS-CoV-2 infection and mRNA vaccination histories profiled 124 using high resolution Spike Phage-DMS library

126 We collected serum samples from two cohorts, termed the Moderna Trial Cohort and the
127 Hospitalized or Ambulatory Adults with Respiratory Viral Infections (HAARVI) Cohort^{24,32}. The
128 Moderna Trial Cohort were participants in a Phase 1 trial and consisted of 49 individuals, 34 who
129 received the 100 µg dose of mRNA-1273 (Moderna) and 15 who received the 250 µg dose. Serum
130 samples were taken at days 36 and 119 post first dose (7 and 90 days post second dose,
131 respectively³². Serum samples were taken at days 36 and 119 post first dose (7 and 90 days post
132 second dose, respectively)³². The HAARVI Cohort included 64 individuals, 44 who had confirmed
133 SARS-CoV-2 infection and 20 who had no reported infection; among this group, 44 were also
134 vaccinated. Those with infection history were stratified by severity based on hospitalization status (39
135 non-hospitalized/mild vs. 5 hospitalized/severe) and serum was sampled at timepoints ranging from 8
136 to 309 days post symptom onset. Of these 44 individuals, 24 were also sampled after vaccination with
137 two doses of either mRNA-1273 (Moderna, n=8) or BNT162b2 (Pfizer/BioNTech, n=15), with 23 from
138 the non-hospitalized group and 1 from the hospitalized group. All 20 SARS-CoV-2 naïve individuals
139 were sampled post-vaccination, with 18 having an additional sample taken pre-vaccination (0 to 98
140 days). Post-vaccination timepoints for all naïve and convalescent individuals ranged from 23 to 65
141 days after the first dose (5 to 42 days after the second dose, respectively). Figure 1 provides an
142 illustration of the two cohorts and their respective samples' infection and vaccination statuses.
143 Additional details are available in Supplementary Table 1.

144 We used a previously described Spike Phage-DMS library to profile the epitopes bound by
145 serum antibodies in the samples described above²⁴. This library consists of peptides displayed on the
146 surface of T7 bacteriophage that are 31 amino acids long, tiling across the length of Spike in one
147 amino acid increments. Peptides in the library correspond to the wild-type Wuhan Hu-1 Spike
148 sequence as well as sequences that contain every possible single amino acid mutation at the central
149 position of the peptide. Serum samples were screened with this library by performing
150 immunoprecipitation (IP) followed by sequencing of the pool of phage enriched by the serum
151 antibodies as previously described^{24,33,34}.

152 Serum antibodies bind to distinct epitopes in infected and vaccinated individuals

153 We first examined the wild-type peptides in the Spike Phage-DMS library that were enriched
154 by each serum sample to determine the epitopes bound by antibodies in each sample from these
155 cohorts (Figure 2A). The major targeted epitopes across all the cohorts were in the NTD, CTD, FP,
156 and SH-H regions. Serum from non-vaccinated infected individuals who were not hospitalized mostly
157 bound to immunodominant epitopes in the FP and SH-H, both of which are epitopes previously
158 identified in infected individuals using Phage-DMS²⁴. Samples from hospitalized/severe COVID-19
159 cases and vaccinated individuals also bound to the FP and SH-H regions, but additionally bound to
160 epitopes within the NTD and CTD regions. In naïve serum samples there were antibodies that
161 occasionally bound to the FP and SH-H peptides. These findings likely reflect that some individuals
162 have preexisting cross-reactive antibodies that bind to these conserved regions between SARS-CoV-
163 2 and endemic coronaviruses, as suggested by previous studies^{16,18}.

164 A Principal Component Analysis (PCA) was used to further investigate differences between the
165 infected and/or vaccinated groups. This analysis indicated that binding to epitopes in the NTD, CTD,
166 FP, and SH-H regions were driving differences between samples (Figure 2B). To quantify differences
167 in antibody binding between groups, for each sample we summed together the enrichment values
168 within each identified epitope region and performed pairwise comparisons between non-hospitalized
169 infected people and all other groups (Figure 2C). Most strikingly, we found non-trivial group
170 differences in the magnitude of humoral responses to these major epitopes on the Spike protein.
171 Specifically, antibodies from both hospitalized infected and vaccinated individuals had significantly
172 higher binding to the NTD, CTD, and SH-H regions compared to non-hospitalized infected individuals.
173 However, antibodies from non-hospitalized infected individuals displayed significantly higher binding
174 to the FP epitope than samples from hospitalized or vaccinated individuals. There was no significant
175 difference in any epitope binding in these four regions between vaccinated samples with and without
176 prior infection ($p > 0.05$, Mann-Whitney-Wilcoxon [M.W.W.]).

177 Effect of age, dose, vaccine type, and timepoint on epitope binding

178 In order to determine if there were covariates that contributed to differences in antibody
179 binding, we examined the effect of participant age, vaccine dose and type, and timepoint post
180 infection or vaccination on binding to the four epitopes identified above (Figure 3). For samples in the
181 Moderna Trial Cohort, there was significantly decreased binding to the CTD epitope and SH-H
182 epitope ($p = 0.008$, $p = 0.011$, Wilcoxon rank-sum test with Bonferroni correction) at the later timepoint
183 post first dose (day 119) compared to the earlier timepoint (day 36) (Figure 3A). To examine the
184 effect of dosage, we compared 100 ug and 250 ug mRNA-1273 groups for those between the age of
185 18 to 55, as that was the only age group included for the 250 ug dose (Figure 3B). There was no

190 significant difference by vaccine dosage for any of the four epitope regions (NTD, CTD, FP, or SH-H).
191 Participant age was also examined as a variable; there appeared to be a difference in epitope binding
192 in the SH-H region, but this did not survive multiple testing correction (Figure 3C).

193 In infected individuals, the effect of time post symptom onset on epitope binding was examined
194 using non-hospitalized infected individuals in the HAARVI Cohort, who were sampled between 26 and
195 309 days post symptom onset (Supplemental Figure 2A). Samples were binned into three groups: 0-
196 60, 60-180, and 180-360 days post symptom onset. At all times post symptom onset there was no
197 significant difference in binding to the four identified epitopes ($p > 0.05$, M.W.W.). Individuals in the
198 HAARVI Cohort were given either the Moderna mRNA-1273 or Pfizer/BioNTech BNT162b2 mRNA
199 vaccine, and comparison of the epitope binding response between the two vaccine types revealed no
200 significant differences in all epitope regions (Supplemental Figure 2B, $p > 0.05$, M.W.W.).

201 202 Infection and vaccination shape pathways of escape

203
204 The Spike Phage-DMS library contains peptides with every possible single amino acid
205 substitution in addition to the wild-type sequence, enabling us to assay the impact of mutations on
206 antibody binding. The effect of site-specific substitutions in critical antibody binding regions not only
207 provides a high-resolution picture of the likely epitope intervals, but also identifies mutations that
208 confer escape within the binding region. The effect of each mutation on serum antibody binding was
209 quantified by calculating its scaled differential selection value, a metric that reports log fold change of
210 mutant binding affinity over wild-type binding affinity at any given site (see Methods)³³. Site mutations
211 that cause a loss of binding when compared to the wild-type peptide centered at that same site are
212 reported as having negative differential selection values, whereas those that bind better than the wild-
213 type peptide have positive differential selection values. In order for differential selection to be
214 meaningful, however, we must ensure that we do not include weak or sporadic signals that may be
215 due to non-specific binding. Accordingly, we set a threshold of summed wild-type peptide binding in
216 any one region. By doing so, we lose samples in the analysis but can be confident in the results
217 presented by samples passing this curation step (Supplemental Figure 3). For samples that passed
218 this threshold, we compared the effect of prior infection and/or time post vaccination on the pathways
219 of escape in each epitope region as follows. Plots depicting the effect of mutations for all samples are
220 publicly explorable at <https://github.com/matsengrp/vacc-dms-view-host-repo>.

221 222 223 *N-Terminal Domain (NTD) and C-terminal Domain (CTD)*

224
225 We examined the sites of escape within the NTD and CTD epitope regions, focusing on
226 vaccinated individuals from the Moderna Trial Cohort because these epitopes were notable targets of
227 the vaccine response and not commonly found in infected individuals. Vaccination elicited antibodies
228 with a strikingly uniform escape profile in the NTD epitope across samples (Figure 4A), with the
229 majority of samples being sensitive to mutation at sites 291, 294-297, 300-302, and 304, which are in
230 the very C terminal portion of NTD as well as the region between NTD and RBD. The CTD region
231 appeared to consist of multiple epitopes, the dominant being located at the N-terminal region between
232 positions 545 to 580 (termed CTD-N). Antibodies that bound to this dominant CTD epitope had a less
233 uniform escape profile, but sites 561 and 562 were common sites of escape in most samples (Figure
234 4B). For antibodies to both the NTD and CTD-N epitopes, the pathways of escape tended to drift over
235 time and were different at 119 days post vaccination as compared to 36 days post vaccination.

236
237

238 *Fusion Peptide (FP)*

239
240 Antibodies against the FP epitope are strongly stimulated after infection but are less strongly
241 induced after subsequent vaccination (Figure 2). Thus, we investigated whether the pathways of
242 escape for serum antibodies also changed after vaccination within samples from previously infected
243 individuals in the HAARVI Cohort. The escape profiles of antibodies in paired samples that strongly
244 bound to the FP epitope both after infection and after subsequent vaccination are shown as a logo
245 plot (Figure 5A). The major sites of escape within the FP epitope for these samples were sites 819,
246 820, 822, and 823, and these sites of escape did not appear to change after vaccination although we
247 noted there was more variability in the escape profiles after vaccination.

248 We next examined the pathways of escape for FP binding antibodies in vaccinated individuals
249 from the Moderna Trial Cohort. In people with no prior infection, vaccination induced diverse
250 pathways of escape in the FP region (Figure 5B). For example, for participant M10 escape was
251 focused on sites 814, 816, and 818, whereas for participant M38 escape was focused on 819, 820,
252 and 823. There appeared to be some differences in the escape profile at 119 days as compared to 36
253 days post vaccination, as exemplified by participants M15, M17, and M20. However, in general many
254 of the major sites of escape were shared at both timepoints within each individual and as a group.

256 *Stem Helix-Heptad Repeat 2 (SH-H)*

257
258 In order to determine the effect of prior infection on the binding profiles of antibodies after
259 vaccination within the SH-H epitope region, we explored the pathways of escape for paired samples
260 from patients with prior infection in the HAARVI Cohort before and after vaccination as was done for
261 the FP region. Samples from previously infected individuals with no vaccination history had diverse
262 pathways of escape within the SH-H epitope (Figure 6A). For example, site 1149 was only sensitive
263 to mutation for participant 217C, and site 1157 was only sensitive to mutations for participants 120C
264 and 146C. In contrast, the samples from vaccinated individuals, regardless of infection history, tended
265 to have a uniform pathway of escape. The most prominent and consistent sites of escape for
266 vaccinated individuals, both with and without prior infection, were at sites 1148, 1152, 1155 and 1156.
267 Of note, the pre-vaccination sample from an individual with prior infection requiring hospitalization
268 (participant 6C) displayed an escape profile highly similar to those from vaccinated individuals, and
269 this escape profile did not change after vaccination.

270 To see whether the pathways of escape changed over time after vaccination, we visualized the
271 escape mutations within the SH-H epitope for the samples in the Moderna Trial Cohort at 36 and 119
272 days after the first dose of vaccine (Figure 6B). We saw a highly uniform pattern of escape for most
273 samples at day 36 and 119, again with escape mainly occurring at sites 1148, 1152, 1155 and 1156.
274 For some participants, such as M11, M34, and M35, the escape mutations appeared to drift over
275 time, but the major sites of escape remained the same.

278 **DISCUSSION**

279
280
281 In this study, we comprehensively profiled the antibody response to the SARS-CoV-2 Spike
282 protein, including pathways of escape from sera in individuals with diverse infection and vaccination
283 histories. We identified four major targets of antibody responses outside of the core RBD domains, in
284 the NTD, CTD, FP, and stem helix-HR2 regions. Vaccinated individuals as well as individuals with
285 severe infection requiring hospitalization both had antibodies to these four epitope regions, whereas

286 individuals with mild infection that did not require hospitalization preferentially targeted only FP and
287 SH-H. In previously infected cases, the epitope binding patterns changed over time after vaccination,
288 with decreased binding to both the CTD and SH-H epitopes. However, there was not uniform decay
289 across all four epitopes, indicating that waning antibody titers may not occur for all epitopes equally.
290 Other factors such as vaccine dose (100 ug or 250 ug), vaccine type (BNT162b2 or mRNA-1273),
291 and participant age did not significantly affect the specificity of the antibody response.

292 We explored the pathways of escape for antibodies binding to these key regions in infected
293 and vaccinated people. We defined for the first time the escape pathways for NTD and CTD-N
294 binding antibodies, epitopes that were commonly found in vaccinated individuals but not in infected
295 individuals. In the case of the NTD epitope, which was located at the C-terminal end of the NTD,
296 escape mutations were uniform and consistent amongst vaccinees, while pathways of escape were
297 more diverse for CTD-N antibodies. Individuals with antibodies that strongly bound the FP epitope
298 had focused escape profiles, with the majority of escape occurring at sites 819, 820, 822, and 823,
299 although the sample size of this group is small (N=3). Vaccination did not greatly alter the escape
300 profile in previously infected individuals, nor did vaccination alone induce a strong or uniform
301 response at the FP epitope. In contrast, antibodies that bind in the SH-H epitope region after infection
302 have diverse pathways of escape, while after vaccination they appear to converge on a more uniform
303 pathway of escape that includes mutations at sites 1148, 1152, 1155 and 1156. Interestingly, these
304 are also the sites of contact for a cross-reactive HR2-specific antibody isolated from a mouse
305 sequentially immunized with the MERS and SARS Spike proteins³⁵. This hints that a singular
306 antibody clonotype could be elicited when exposed to a stabilized Spike protein, dominating the
307 response in the SH-H region.

308 We also observed some drift in the pathways of escape within a single person over time after
309 vaccination. This mirrors findings from a recent study that examined sites of escape for RBD-specific
310 antibodies in serum samples from the same Moderna Trial Cohort as used in this study²³. Together
311 these results suggest that the B cell response after vaccination with Spike mRNA continues to evolve
312 over time. Multiple studies have demonstrated that SARS-CoV-2-specific B cells undergo continued
313 somatic hypermutation in the months after infection, likely due to antigen persistence^{36,37}. Spike
314 antigen has been detected in the lymph nodes at least 3 months after vaccination with BNT162b2,
315 and continued maturation of germinal center B cells could be a possible explanation for the changes
316 in epitope binding we observed³⁸. Alternatively, turnover of short-term plasma cells and memory B
317 cells could account for loss of antibody binding to certain epitopes.

318 Our study has important limitations worth noting. Because the Spike Phage-DMS library
319 displays 31 amino acid peptides, we are unable to detect antibodies that bind to conformational
320 epitopes and/or glycosylated epitopes. This is demonstrated by the lack of observable binding to the
321 RBD region, a domain with complex folding and known target of antibodies from infected and
322 vaccinated individuals. However, prior studies of RBD epitopes have already been reported using an
323 overlapping set of samples from the HAARVI Cohort, however, and together these results paint a
324 more complete picture of epitopes across the Spike protein^{15,23}. Finally, we only have 5 individuals
325 within the hospitalized group and this small sample size limits our ability to make conclusions about
326 epitope binding in those with severe infection.

327 Our finding that vaccinated individuals have a broader response across the Spike protein than
328 infected individuals may have important implications for immune durability against future SARS-CoV-
329 2 variants. Evidence suggests that a polyclonal antibody response that is resistant in the face of
330 multiple mutations is necessary for long-lasting immunity against a mutating viral pathogen³⁹. Thus,
331 the polyclonal response to vaccination may provide greater protection from infection than the more
332 focused response after infection. However, the number of epitopes targeted provides just one
333 benchmark and the ability to escape at the population level could also be influenced by the diversity

of individuals' antibody responses at each epitope and thus the likelihood that a single escape mutation could be widely selected. At one S2-domain epitope region (SH-H) vaccination induced uniform sites of escape that may be due to a singular type of antibody that would allow escape by the same mutations for all vaccinated people. However, epitopes in the S2 domain tend to be in highly conserved regions with important functions that constrain the virus' ability to mutate, making escape from these antibodies less likely than for RBD, where escape is already common. Indeed, mutations in the FP and SH-H epitopes are not arising in the global population of SARS-CoV-2²⁴, providing some suggestion that these regions may be constrained^{40,41}. Overall, further studies of the functional capacity of these vaccine-elicited antibodies targeting epitopes outside of RBD are warranted, to provide a path towards a polyclonal response to epitopes across the full Spike protein. This comprehensive view may further the goal of a more universal coronavirus vaccine that eliminates the need for continual updates of the SARS-CoV-2 vaccine strain due to mutations in variable regions on Spike.

MATERIALS AND METHODS

Sample collection

Moderna Trial Cohort

We obtained post-vaccination serum samples via the National Institute of Allergy and Infection Disease that were taken as part of a phase I clinical trial testing the safety and efficacy of the Moderna mRNA-1273 vaccine (NCT04283461)³². All samples were de-identified and thus all work was approved by the Fred Hutchinson Cancer Research Center Institutional Review Board as nonhuman subjects research. Trial participants were given either 100 ug or 250 ug doses of the mRNA-1273 vaccine, and serum was sampled from all trial participants at 36 days and 119 days post vaccination. See Table 1 for detailed metadata related to each participant and serum sample.

HAARVI Cohort

We obtained plasma samples from individuals enrolled in the Hospitalized or Ambulatory Adults with Respiratory Viral Infections (HAARVI) study conducted in Seattle²⁴. Individuals were either enrolled upon PCR confirmed diagnosis with SARS-CoV-2 infection or as control subjects prior to receiving vaccination with either BNT162b2 (Pfizer/BioNTech) or mRNA-1273 (Moderna). See Table 1 for detailed metadata related to each participant and plasma sample. For convenience, all plasma and serum samples in this study are referred to as serum. This study was approved by the University of Washington Institutional Review Board.

Spike Phage-DMS assay

The Spike Phage-DMS library used in this study contained 24,820 designed peptides that tile across the length of the Spike protein. Peptides are each 31 amino acids long and tile by 1 amino acid increments, and correspond to either the wild-type sequence or a sequence containing a single mutation. Serum samples were profiled using the Spike Phage-DMS library as previously described²⁴. Following this method, the Spike Phage-DMS library was diluted in Phage Extraction Buffer (20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 6 mM MgSO₄) to a concentration of 2.964 x 10⁹ plaque forming

units/mL, which corresponds to approximately 200,000-fold coverage of each peptide. 10 uL of serum or plasma was added to 1 mL of the diluted library and incubated in a deep 96-well plate overnight at 4°C on a rotator. 40uL of a 1:1 mixture of Protein A and Protein G Dynabeads (Invitrogen) were added to each well and then incubated at 4°C for 4 hours on a rotator. Beads bound to the antibody-phage complex were magnetically separated and washed 3x with 400 uL wash buffer (150 mM NaCl, 50 mM Tris-HCl, 0.1% [vol/vol] NP-40, pH 7.5). Beads were resuspended in 40 uL of water and lysed at 95°C for 10 minutes. The diluted Spike Phage-DMS library was also lysed to capture the starting frequencies of peptides. All samples were run twice, once each with two independently generated Spike Phage-DMS libraries.

DNA from lysed samples were amplified and sequenced as previously described²⁴. Two rounds of PCR were performed using Q5 High-Fidelity 2X Master Mix (NEB). For the first round of PCR, 10uL of lysed phage was used as the template in a 25 uL reaction using primers described in ²⁴. For the second round of PCR, 2 uL of the round 1 PCR product was then used as the template in a 50 uL reaction, with primers that add dual indexing sequences on either side of the insert. PCR products were then cleaned using AMPure XP beads (Beckman Coulter) and eluted in 50 uL water. DNA concentrations were quantified via Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen). Equimolar amounts of DNA from the samples, along with 10X the amount of the input library samples, was pooled, gel purified, and the final library was quantified using the KAPA Library Quantification Kit (Roche). Pools were sequenced on an Illumina HiSeq 2500 machine using the rapid run setting with single end reads.

Sample curation and replicate structure

All sample IP's and downstream analysis were run in duplicate across two separate phage display library batches to ensure reproducibility, with the exception of the four acute samples from hospitalized HAARVI participants which were run in singlicate. All results were cross checked with the set of batch replicates to ensure significance fell within one order of magnitude where applicable. For brevity, we present only figures resulting from the single complete set of batch-specific replicates, however, all figures using the second set of library batch replicates are available (see Code and Data Availability). Additionally, some samples were run with "in-line" technical replicates within the same batch. In the case with more than one technical replicate, we selected the sample with the highest reads mapped from each set of batch replicates for our downstream analysis.

Short read alignment and peptide counts processing

Samples were aliquoted and sequenced targeting 10X coverage of total sample reads to the peptide library reference. We demultiplexed samples using Illumina MiSeq Reporter software. Post sample demultiplexing, we used a *Nextflow* pipeline to process the peptide counts as well as alignment stats for all samples⁴². The tools and parameters describing the workflow are as follows. The index creation and short-read alignment step were done using *Bowtie2*. During alignment we allowed for zero mismatches in the default seed length of each read (20, very sensitive) after trimming 32 bases from the 3' end of each 125bp read to match the 93 bp peptides in our reference library⁴³. *Samtools* was subsequently used to gather sequencing statistics as well as produce the final peptide counts using the *stats* and *idxstats* modules. Finally, the pipeline collected all reference peptide alignment counts and merges them into a single *xarray* dataset coupling sample and peptide

429 metadata with their respective count. Alignment stats for all replicates are seen in Supplementary
430 Figure S6.

431 Each of the processing steps described here, as well as downstream analysis and plotting,
432 were run using static and freely available Docker containers for reproducibility. We provide an
433 automated workflow and the configuration scripts defining exact parameters. See Code and Data
434 Availability section for more information.

437 Epitope binding region identification

439 Principal Component Analysis (PCA) via Singular Value Decomposition (SVD) was performed
440 on each set of batch replicates using the scikit-learn package⁴⁴. We first subset our dataset to only
441 include wildtype peptide count enrichments from either infected or vaccinated individuals as input.
442 This curation resulted in the matrix, X of size $n \times p$ with n biologically distinct replicates and p
443 enrichment features across the spike protein. All enrichment values were calculated as a fold change
444 in the frequency for any one sample enrichment over the library control enrichment at the same sites.
445 Each feature was mean centered before performing the PCA such that the covariance matrix of X is
446 equivalent to $X^T X / (n - 1)$. We can then use the eigendecomposition, $X = USV^T$, to describe the data.
447 The principal axes in feature space are then represented by the columns of V and represent the
448 direction of maximum variance in the data. Figure S1 shows three facets of this decomposition;
449 Figure S1A: the unit scaled sample “scores” represented by the columns to visualize sample
450 relationship in principal component space; Figure S1B: component loadings (scaled by the square
451 root of the respective eigenvalues in S); and Figure S1C: the first three principal axes/directions in
452 feature space plotted as a function of the WT peptide feature location on the Spike protein. Together,
453 these provide a visualization of key features in the data used in our downstream analysis. We chose
454 our epitope regions as contiguous regions of nonzero value in the loadings in the first three principal
455 axes.

458 Identifying high-resolution pathways of escape

460 In order to ensure reliable measurements of differential selection of single AA variants
461 compared to the ancestral sequence variant, we threw out samples whose respective sum of wild-
462 type enrichment was below a threshold set for each of the defined binding regions (Figure S4). Once
463 curated, we computed the log-fold change in each of the 19 possible variant substitutions at each
464 site. This metric was then scaled by the average of the wild-type sequence enrichment coupled with
465 both the preceding and following wild-type peptide enrichments at any given site. To evaluate escape
466 at each site, we then sum the differential selection metric as described for each variant at a site to
467 examine a more complete picture of the data defining escape patterns in each sample group.

470 **CODE AND DATA AVAILABILITY**

471 We provide a fully reproducible automated workflow which ingests raw sequencing data and
472 performs all analyses presented in the paper. The workflow defines and runs the processing steps
473 within publicly available and static Docker software containers, including *hippery* and *hip-flow*
474 described in the Methods section. The source code, Nextflow script, software dependencies, and
475

instructions for re-running the analysis can be found at <https://github.com/matsengrp/phage-dms-vacc-analysis>.

The generalized PhIP-Seq alignment and count generation pipeline script can be found at <https://github.com/matsengrp/philp-flow>. A template and documentation for the alignment pipeline configuration is available at <https://github.com/matsengrp/philp-flow-template>. Finally, we provide a python API, *phipperry*, to query the resulting dataset post-alignment that can be found at <https://github.com/matsengrp/phipperry>.

All raw sequencing data was submitted to the NCBI SRA under PRJNA765705. Pre-processed enrichment data is available upon request. Additionally, differential selection data and more can be explored interactively using the dms-view toolkit available at <https://github.com/matsengrp/vacc-dms-view-host-repo>.

For more information regarding code and data availability, please email jgallowa@fredhutch.org. For original data from the NIH Moderna trial please see Jackson *et al*^{β2}, and for information on the HAARVI cohort please contact HYC.

STATISTICAL ANALYSIS

Estimates of significance presented between group continuous distributions of wild-type enrichment were reported using a *Mann-Whitney Wilcoxon* test with the exception of analysis that included only paired longitudinal samples - such as the comparison of 36-and-119 Days post-vaccination - in this case we used a *Wilcoxon signed-rank* test. Bonferroni correction was applied where applicable and adjusted *P* values < 0.05 were presented as significant. All statistical analysis were done using *Python 3.6* and plotted using the *statannot* package found here <https://github.com/webermarcolivier/statannot>. The static Docker container used for all statistical analysis is publicly hosted at <https://quay.io/repository/matsengrp/vacc-ms-analysis>.

ACKNOWLEDGEMENTS

We thank Kevin Sung, Thayer Fisher, and Noah Simon for providing advice regarding computational analyses. We thank Cassie Sather and the Genomics core facility for assistance with sequencing. We thank Laura Jackson (Kaiser Permanente), Chris Roberts, Catherine Luke, and Rebecca Lampley [National Institute of Allergy and Infectious Diseases (NIAID), NIH] for assistance with obtaining the mRNA-1273 phase 1 trial vaccine samples. We also thank all research participants and study staff of the Hospitalized or Ambulatory Adults with Respiratory Viral Infections (HAARVI) study. This work was supported by NIH grants AI138709 (PI Overbaugh) and AI146028 (PI Matsen). Julie Overbaugh received support as the Endowed Chair for Graduate Education (FHCRC). The research of Frederick Matsen was supported in part by a Faculty Scholar grant from the Howard Hughes Medical Institute and the Simons Foundation. Scientific Computing Infrastructure at Fred Hutch was funded by ORIP grant S10OD028685.

CONTRIBUTIONS

J.O. and F.A.M. conceived the project; M.E.G., J.G., F.A.M., and J.O. led the design of the study; H.Y.C. led the HAARVI study, with C.R.W., J.K.L., and N.F. involved in sample collection.

M.E.G. performed all experiments, and J.G. performed all computational and data analyses with F.A.M. advising. M.E.G., J.G., F.A.M., and J.O. wrote the paper with input from all authors.

ETHICS DECLARATIONS

Competing Interests

H.Y.C. reported consulting with Ellume, Pfizer, The Bill and Melinda Gates Foundation, Glaxo Smith Kline, and Merck. She has received research funding from Gates Ventures, Sanofi Pasteur, and support and reagents from Ellume and Cepheid outside of the submitted work.

FIGURES





FIGURE 1: A schematic of sample cohorts. Characteristics of individual participants sampled as part of the Moderna Trial Cohort (left) or the HAARVI Cohort (right). Sample sizes of unique individuals in each group are designated below each figure.



549
550
551 **FIGURE 2: Enrichment of wild-type peptides by serum antibodies.** (A) Heatmap with a sample in
552 each row and groups of samples colored on the left. Columns represent peptide locations, with each
553 square on the heatmap indicating the summed enrichment value within a 10-peptide interval. Darker
554 purple indicates higher enrichment values, and values above 150 were capped. Transparent boxes
555 above the heatmap annotate the Spike protein domains, while the smaller grey boxes indicate
556 *epitope binding regions* defined in this analysis (B) The loading vectors from the PCA analysis with
557 the four epitope sites highlighted; enrichments in each of these regions are summed together for
558 subsequent analysis. (C) Box plots describing the distribution of summed wild-type enrichment values
559 for each sample within each of the four epitope sites, each named according to its associated protein
560 domain. Color indicates the sample group. The bars between boxplots give statistical significance (p-
561 value) tests using a Mann-Whitney-Wilcoxon test. All sample group comparisons with the non-
562 hospitalized infected group were performed, and only significant values are shown.
563
564
565
566
567
568





FIGURE 3: Comparison of epitope binding for NIH Moderna Trial subgroups. Boxplots of summed wild-type enrichment within epitope binding regions for samples grouped by (A) timepoint post vaccination, (B) vaccine dose, or (C) participant age. Samples were taken at either at 36 (n=64) or 119 (n=64) days post vaccination. (B) and (C) are additionally separated by timepoint post vaccination. Results of a Wilcoxon rank-sum test between the groups appears only where $p < 0.05$ after Bonferroni multiple testing correction (36 group comparisons). Figures containing all p-values for both replicate batches are available at <https://github.com/matsengrp/phage-dms-vacc-analysis>.


N-Terminal Domain (NTD) scaled differential selection

Moderna Trial Cohort



C-Terminal Domain (CTD-N) scaled differential selection

Moderna Trial Cohort




■ Acidic ■ Basic ■ Hydrophobic ■ Neutral ■ Polar

579
580
581
582
583
584
585
586
587
588

FIGURE 4: NTD and CTD-N epitope escape profiles. (A and B) Logo plots depicting the effect of mutations on epitope binding in either the NTD (A) or CTD-N (B) epitope for paired samples from the Moderna Trial Cohort. The height of the letters corresponds to the magnitude of the effect of that mutation on epitope binding, i.e. its scaled differential selection value. Letters below zero indicate mutations that cause poorer antibody binding as compared to wild-type peptide, and letters above zero indicate mutations that bind better than the wild-type peptide. Letter colors denote the chemical property of the amino acids. Logo plots on the left and right are paired samples from the same individual, with the participant ID noted on the left.

Fusion Peptide (FP) scaled differential selection



589
590
591
592
593
594
595
596
597

FIGURE 5: FP epitope escape profiles. (A and B) Logo plots depicting the effect of mutations on epitope binding within the FP epitope region for paired samples from the (A) HAARVI Cohort or (B) Moderna Trial Cohort. Details are as described in Fig 4.

Stem Helix-HR2 (SH-H) scaled differential selection






FIGURE 6: SH-H epitope escape profiles. (A and B) Logo plots depicting the effect of mutations on epitope binding within the SH-H epitope region for paired samples from the (A) HAARVI Cohort or (B) Moderna Trial Cohort. Details are as described in Fig 4.

598
599
600
601
602

603 **SUPPLEMENTAL FIGURES**
 604
 605 Supplemental Figure 1




606 **SUPPLEMENTAL FIGURE 1: Principal Component Analysis on wild-type enrichment features**
 607 **of all samples** (A) Scatterplot depicting the unit scaled sample “scores” represented by the columns
 608 to visualize sample relationship in principal component space. Colors represent the group which each
 609 sample belongs to. (B) Vector plots showing the component loadings, scaled by the square root of the
 610 respective eigenvalues in the eigen-decomposition. Colors represent the genomic location of each
 611 component loading score. (C) Line plots showing the first three principal axes/directions in feature
 612 space, plotted as a function of the wild-type peptide feature location on Spike.
 613
 614
 615
 616
 617



618
619
620
621
622
623
624
625
626
627

SUPPLEMENTAL FIGURE 2: Comparison of epitope binding for HAARVI subgroups. Boxplots of summed wild-type enrichment within epitope binding regions for samples grouped by (A) timepoint post symptom onset or (B) vaccine type (Pfizer/BioNTech BNT162b2 or Moderna mRNA-1273). Results of a Mann-Whitney test between the groups are shown. P-values were adjusted for multiple testing using Bonferroni correction. * indicates $p < 0.05$, ns means “not significant”.

628
629



630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656

SUPPLEMENTAL FIGURE 3: Thresholding of total epitope binding within major epitope regions. Histogram showing the summed enrichment values within each epitope region for every sample in the Moderna Trial Cohort (left two panels) or HAARVI Cohort (right two panels). Blue line delineates the threshold chosen for each epitope region. Samples above the line were included in the escape profile analyses.

CITATIONS

- 1 Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* **383**, 2603-2615, doi:10.1056/NEJMoa2034577 (2020).
- 2 Keehner, J. *et al.* SARS-CoV-2 Infection after Vaccination in Health Care Workers in California. *N Engl J Med* **384**, 1774-1775, doi:10.1056/NEJMc2101927 (2021).
- 3 Amit, S., Regev-Yochay, G., Afek, A., Kreiss, Y. & Leshem, E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. *Lancet* **397**, 875-877, doi:10.1016/s0140-6736(21)00448-7 (2021).
- 4 Angel, Y. *et al.* Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers. *Jama*, doi:10.1001/jama.2021.7152 (2021).
- 5 Thompson, M. G. *et al.* Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021. *MMWR Morb Mortal Wkly Rep* **70**, 495-500, doi:10.15585/mmwr.mm7013e3 (2021).
- 6 Haas, E. J. *et al.* Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. *Lancet*, doi:10.1016/s0140-6736(21)00947-8 (2021).
- 7 Baden, L. R. *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* **384**, 403-416, doi:10.1056/NEJMoa2035389 (2021).
- 8 Planas, D. *et al.* Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature*, doi:10.1038/s41586-021-03777-9 (2021).
- 9 Lopez Bernal, J. *et al.* Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *N Engl J Med*, doi:10.1056/NEJMoa2108891 (2021).
- 10 Eguia, R. T. *et al.* A human coronavirus evolves antigenically to escape antibody immunity. *PLoS Pathog* **17**, e1009453, doi:10.1371/journal.ppat.1009453 (2021).
- 11 Edridge, A. W. D. *et al.* Seasonal coronavirus protective immunity is short-lasting. *Nat Med* **26**, 1691-1693, doi:10.1038/s41591-020-1083-1 (2020).
- 12 Hendley, J. O., Fishburne, H. B. & Gwaltney, J. M., Jr. Coronavirus infections in working adults. Eight-year study with 229 E and OC 43. *Am Rev Respir Dis* **105**, 805-811, doi:10.1164/arrd.1972.105.5.805 (1972).
- 13 Schmidt, O. W., Allan, I. D., Cooney, M. K., Foy, H. M. & Fox, J. P. Rises in titers of antibody to human coronaviruses OC43 and 229E in Seattle families during 1975-1979. *Am J Epidemiol* **123**, 862-868, doi:10.1093/oxfordjournals.aje.a114315 (1986).
- 14 Hanrath, A. T., Payne, B. A. I. & Duncan, C. J. A. Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection. *J Infect* **82**, e29-e30, doi:10.1016/j.jinf.2020.12.023 (2021).
- 15 Greaney, A. J. *et al.* Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. *Cell Host Microbe*, doi:10.1016/j.chom.2021.02.003 (2021).
- 16 Shrock, E. *et al.* Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. *Science*, doi:10.1126/science.abd4250 (2020).
- 17 Li, Y. *et al.* Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients. *Cell Rep* **34**, 108915, doi:10.1016/j.celrep.2021.108915 (2021).

- 705 18 Stoddard, C. I. *et al.* Epitope profiling reveals binding signatures of SARS-CoV-2 immune
706 response in natural infection and cross-reactivity with endemic human CoVs. *Cell Rep* **35**,
707 109164, doi:10.1016/j.celrep.2021.109164 (2021).
- 708 19 Corbett, K. S. *et al.* SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen
709 preparedness. *Nature* **586**, 567-571, doi:10.1038/s41586-020-2622-0 (2020).
- 710 20 Goel, R. R. *et al.* Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and
711 recovered individuals following mRNA vaccination. *Sci Immunol* **6**,
712 doi:10.1126/sciimmunol.abi6950 (2021).
- 713 21 Prendecki, M. *et al.* Effect of previous SARS-CoV-2 infection on humoral and T-cell responses
714 to single-dose BNT162b2 vaccine. *Lancet* **397**, 1178-1181, doi:10.1016/s0140-
715 6736(21)00502-x (2021).
- 716 22 Edara, V. V., Hudson, W. H., Xie, X., Ahmed, R. & Suthar, M. S. Neutralizing Antibodies
717 Against SARS-CoV-2 Variants After Infection and Vaccination. *Jama*,
718 doi:10.1001/jama.2021.4388 (2021).
- 719 23 Greaney, A. J. *et al.* Antibodies elicited by mRNA-1273 vaccination bind more broadly to the
720 receptor binding domain than do those from SARS-CoV-2 infection. *Sci Transl Med* **13**,
721 doi:10.1126/scitranslmed.abi9915 (2021).
- 722 24 Garrett, M. E. *et al.* High-resolution profiling of pathways of escape for SARS-CoV-2 spike-
723 binding antibodies. *Cell* **184**, 2927-2938.e2911, doi:10.1016/j.cell.2021.04.045 (2021).
- 724 25 Piccoli, L. *et al.* Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike
725 Receptor-Binding Domain by Structure-Guided High-Resolution Serology. *Cell* **183**, 1024-
726 1042.e1021, doi:10.1016/j.cell.2020.09.037 (2020).
- 727 26 Poh, C. M. *et al.* Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising
728 antibodies in COVID-19 patients. *Nat Commun* **11**, 2806, doi:10.1038/s41467-020-16638-2
729 (2020).
- 730 27 Li, Y. *et al.* Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in
731 COVID-19 patients. *Cell Mol Immunol*, doi:10.1038/s41423-020-00523-5 (2020).
- 732 28 Schäfer, A. *et al.* Antibody potency, effector function, and combinations in protection and
733 therapy for SARS-CoV-2 infection in vivo. *J Exp Med* **218**, doi:10.1084/jem.20201993 (2021).
- 734 29 Tausin, A. *et al.* A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated
735 antibody effector functions and T cell responses. *Cell Host Microbe*,
736 doi:10.1016/j.chom.2021.06.001 (2021).
- 737 30 Winkler, E. S. *et al.* Human neutralizing antibodies against SARS-CoV-2 require intact Fc
738 effector functions for optimal therapeutic protection. *Cell* **184**, 1804-1820.e1816,
739 doi:10.1016/j.cell.2021.02.026 (2021).
- 740 31 Ullah, I. *et al.* Live imaging of SARS-CoV-2 infection in mice reveals neutralizing antibodies
741 require Fc function for optimal efficacy. *bioRxiv*, doi:10.1101/2021.03.22.436337 (2021).
- 742 32 Jackson, L. A. *et al.* An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. *N Engl J*
743 *Med* **383**, 1920-1931, doi:10.1056/NEJMoa2022483 (2020).
- 744 33 Garrett, M. E. *et al.* Phage-DMS: A Comprehensive Method for Fine Mapping of Antibody
745 Epitopes. *iScience* **23**, doi:10.1016/j.isci.2020.101622 (2020).
- 746 34 Mohan, D. *et al.* PhIP-Seq characterization of serum antibodies using oligonucleotide-encoded
747 peptidomes. *Nat Protoc* **13**, 1958-1978, doi:10.1038/s41596-018-0025-6 (2018).
- 748 35 Sauer, M. M. *et al.* Structural basis for broad coronavirus neutralization. *Nat Struct Mol Biol* **28**,
749 478-486, doi:10.1038/s41594-021-00596-4 (2021).
- 750 36 Gaebler, C. *et al.* Evolution of antibody immunity to SARS-CoV-2. *Nature* **591**, 639-644,
751 doi:10.1038/s41586-021-03207-w (2021).

- 752 37 Sakharkar, M. *et al.* Prolonged evolution of the human B cell response to SARS-CoV-2
753 infection. *Sci Immunol* **6**, doi:10.1126/sciimmunol.abg6916 (2021).
- 754 38 Turner, J. S. *et al.* SARS-CoV-2 mRNA vaccines induce persistent human germinal centre
755 responses. *Nature*, doi:10.1038/s41586-021-03738-2 (2021).
- 756 39 Greaney, A. J., Welsh, F. C. & Bloom, J. D. Co-dominant neutralizing epitopes make anti-
757 measles immunity resistant to viral evolution. *Cell Rep Med* **2**, 100257,
758 doi:10.1016/j.xcrm.2021.100257 (2021).
- 759 40 Walls, A. C. *et al.* Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.
760 *Cell* **181**, 281-292.e286, doi:10.1016/j.cell.2020.02.058 (2020).
- 761 41 Jaroszewski, L., Iyer, M., Alisoltani, A., Sedova, M. & Godzik, A. The interplay of SARS-CoV-2
762 evolution and constraints imposed by the structure and functionality of its proteins. *PLoS*
763 *Comput Biol* **17**, e1009147, doi:10.1371/journal.pcbi.1009147 (2021).
- 764 42 Di Tommaso, P. *et al.* Nextflow enables reproducible computational workflows. *Nat Biotechnol*
765 **35**, 316-319, doi:10.1038/nbt.3820 (2017).
- 766 43 Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nat Methods* **9**,
767 357-359, doi:10.1038/nmeth.1923 (2012).
- 768 44 Pedregosa, F. *et al.* Scikit-learn: Machine Learning in Python. *J. Mach. Learn. Res.* **12**, 2825–
769 2830 (2011).
- 770
771
772
773
774